1. Home
  2. TVRD vs CLBR Comparison

TVRD vs CLBR Comparison

Compare TVRD & CLBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVRD
  • CLBR
  • Stock Information
  • Founded
  • TVRD 2017
  • CLBR 2023
  • Country
  • TVRD United States
  • CLBR United States
  • Employees
  • TVRD N/A
  • CLBR N/A
  • Industry
  • TVRD Biotechnology: Pharmaceutical Preparations
  • CLBR
  • Sector
  • TVRD Health Care
  • CLBR
  • Exchange
  • TVRD Nasdaq
  • CLBR Nasdaq
  • Market Cap
  • TVRD 246.5M
  • CLBR 279.4M
  • IPO Year
  • TVRD N/A
  • CLBR 2023
  • Fundamental
  • Price
  • TVRD $28.34
  • CLBR $15.39
  • Analyst Decision
  • TVRD Strong Buy
  • CLBR
  • Analyst Count
  • TVRD 2
  • CLBR 0
  • Target Price
  • TVRD $52.00
  • CLBR N/A
  • AVG Volume (30 Days)
  • TVRD 48.4K
  • CLBR 922.8K
  • Earning Date
  • TVRD 05-13-2025
  • CLBR 01-01-0001
  • Dividend Yield
  • TVRD N/A
  • CLBR N/A
  • EPS Growth
  • TVRD N/A
  • CLBR N/A
  • EPS
  • TVRD N/A
  • CLBR 0.19
  • Revenue
  • TVRD N/A
  • CLBR N/A
  • Revenue This Year
  • TVRD N/A
  • CLBR N/A
  • Revenue Next Year
  • TVRD N/A
  • CLBR N/A
  • P/E Ratio
  • TVRD N/A
  • CLBR $80.76
  • Revenue Growth
  • TVRD N/A
  • CLBR N/A
  • 52 Week Low
  • TVRD $8.13
  • CLBR $10.15
  • 52 Week High
  • TVRD $34.31
  • CLBR $15.49
  • Technical
  • Relative Strength Index (RSI)
  • TVRD N/A
  • CLBR 78.55
  • Support Level
  • TVRD N/A
  • CLBR $13.61
  • Resistance Level
  • TVRD N/A
  • CLBR $15.30
  • Average True Range (ATR)
  • TVRD 0.00
  • CLBR 0.77
  • MACD
  • TVRD 0.00
  • CLBR 0.12
  • Stochastic Oscillator
  • TVRD 0.00
  • CLBR 96.39

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

About CLBR Colombier Acquisition Corp. II

Colombier Acquisition Corp II is a blank check company.

Share on Social Networks: